Furthermore, low expression of FOXF2 was associated with the worst outcome of NSCLC patients with clinical stage I. And two independent validation studies (n = 98 and n = 1928 respectively) confirmed our findings. This evidence concerns the gene FOXF2 and non-small cell lung carcinoma.